ArriVent BioPharma, Inc. (AVBP) vs CorMedix Inc. (CRMD)

A side-by-side comparison of ArriVent BioPharma, Inc. and CorMedix Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
ArriVent BioPharma, Inc. logo
AVBP
ArriVent BioPharma, Inc.
$703M
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
CorMedix Inc. logo
CRMD
CorMedix Inc.
$571M
$7.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AVBP vs CRMD

growth of $100 · dividends reinvested · last 3y
AVBP +42.3% (+12.5%/yr)CRMD +121.3% (+30.3%/yr)CRMD compounded faster over this window
100200300400500Start $10020252026$142$221
AVBP CRMD

AVBP vs CRMD: by the numbers

  • •AVBP is the larger company ($703M vs $571M market cap).
  • •CRMD is profitable (40.49% net margin) while AVBP runs a net loss (0.00%).

Metrics side by side

Valuation

MetricAVBPCRMD
P/E ratioN/A3.42
Forward P/EN/A14.71
P/S ratioN/A1.24
P/B ratio1.921.24
EV / EBITDAN/A1.82
FCF yieldN/A43.82%

Profitability

MetricAVBPCRMD
Gross margin0.00%82.78%
Operating margin0.00%46.95%
Net margin0.00%40.49%
ROE-44.63%40.62%
ROIC-47.96%27.87%

Growth (annualized)

MetricAVBPCRMD
Revenue CAGR (5Y)N/A352.03%
Total return CAGR (5Y)N/A9.70%

Frequently asked

Is AVBP or CRMD more profitable?
CRMD runs the higher net margin — AVBP at 0.00% versus CRMD at 40.49%.

Go deeper

Full AVBP analysisFull CRMD analysisInteractive comparison tool

Dig into the metrics

CorMedix P/E ratioArriVent BioPharma ROECorMedix ROEArriVent BioPharma operating marginCorMedix operating marginArriVent BioPharma revenue growthCorMedix revenue growthArriVent BioPharma free cash flowCorMedix free cash flow

ArriVent BioPharma & CorMedix appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksHighest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.